Oral drops therapy that mimics natural GLP-1 to improve appetite control and metabolic efficiency
The intercostal muscles, connective tissue, and often the cartilage connecting ribs to the sternum all sustain injury in thoracic trauma
Appetite suppression through dopamine modulation Central appetite control: Tesofensine acts on hypothalamus Affects arcuate nucleus (appetite center) Different pathway from GLP-1 receptors Direct neurotransmitter modulation Rapid onset (hours not days) Dopamine's role in eating: Mediates food reward (hedonic eating) High-dopamine = reduced food seeking Decreases obsessive food thoughts Reduces binge eating tendencies Similar to ADHD medication effects Subjective appetite changes reported: Reduced hunger (moderate, not as strong as semaglutide ) Less food preoccupation Earlier satiety (smaller portions satisfying) Reduced cravings especially for high-calorie foods More mental focus on non-food activities Appetite suppression comparison: Why dopamine approach different: Addresses psychological/behavioral eating Reduces food as reward behavior Helps with emotional eating Less GI side effects than GLP-1s But creates stimulant-like dependency risk Clinical trial results and efficacy Evidence from human studies
Bright mornings and dim evenings should complement any Epitalon protocol
Gray market products exist in an in-between space, since theyre not exactly illegal, but are obtained through channels that lack proper authorization for personal use, says Dr
Chronic Fatigue Syndrome is an acquired neurological channelopathy
